Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/24761
Title: COPD as a risk factor for Coronary Artery Disease (CAD): Overview of 10-year atherosclerotic cardiovascular disease (ASCVD) risk assessment
Authors: Buklioska Ilievska, Daniela 
Mickovski Ivana
Baloski Marjan
Doneva Daniela
Neshovska Radmila
Simeonova Magdalena
Nedeska Minova Natasha
Prgova, Biljana 
Minov, Jordan 
Kochovska Kamchevska Nade
Bushev Jane
Trajkovska Vanche
Keywords: COPD
COPD - management
chronic diseases
Issue Date: 1-Dec-2022
Source: Buklioska Ilievska D et al. COPD as a risk factor for Coronary Artery Disease (CAD): Overview of 10-year atherosclerotic cardiovascular disease (ASCVD) risk assessment. European Respiratory Journal Sep 2022, 60 (suppl 66) 323
Journal: European Respiratory Journal
Conference: European Respiratory Society International Congress, Barcelona, September 2022
Abstract: We aimed to investigate the association between COPD and CAD (overview of 10-year risk of fatal cardiovascularevent), and the relation to the severity of airflow limitation.Cross-sectional study including 220 patients with stable COPD as investigated group (IG), aged 40 to 75 yearsand 58 non-COPD subjects, matched by gender, age, BMI, smoking status, as control group (CG). All studysubjects underwent pulmonary, cardiological evaluation, lipid and glycemic status.The analysis compared the 10-year established ASCVD risk between COPD stages (according to GOLDclassification 1, 2, 3, 4) and between IG vs. CG. ASCVD score was classified as low (score <5%), borderline (5 to<7.5%), moderate (≥7.5 to <20) and high risk (score ≥20%). Results presented statistically significant differencebetween mean ASCVD value in IG 21,69±13,86% vs. CG 15,83±9,92% (p=0.0028). The median risk of ASCVDfor fatal cardiovascular events was high in IG and moderate in CG. The mean and median values of 10-yearASCVD risk in the IG subgroups were: GOLD1 16,79±8,04% (50% of the subjects with risk >15,7%), GOLD222,67±16,49% (50% of the subjects with risk >20,6%), GOLD3 26,81±14,15% (50% of the subjects with risk >27,6%) and GOLD4 20,70±13,52% (50% of the subjects with risk > 18,4%). The average ASCVD risk of fatalcardiovascular event was moderate in GOLD1 and GOLD4, and high in GOLD2 and GOLD3.We found higher risk for fatal cardiovascular outcome in patients with COPD, even in the early COPD stages(GOLD2), compared to non-COPD group. Our findings suggest that an urgent need to develop comprehensivestrategies for prevention, screening and early treatment are needed.
URI: http://hdl.handle.net/20.500.12188/24761
Appears in Collections:Faculty of Medicine: Conference papers

Files in This Item:
File Description SizeFormat 
ERS2022 European Respiratory Journal.pdf397.5 kBAdobe PDFView/Open
Show full item record

Page view(s)

33
checked on Apr 26, 2024

Download(s)

6
checked on Apr 26, 2024

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.